Estrogen Patch Shortage Has No Clear End Date. Here Is What Women and Doctors Are Doing About It.

The Numbers Behind the Shortage

Prescriptions for estrogen patches did NOT tick up slightly — they exploded. According to health data company Truveta, patch use more than tripled between 2018 and early 2026. Among women ages 45 to 54, prescribing rates jumped 184%. By February 2026, roughly 1 in 20 women in that age group had an active estrogen-based HRT prescription.

HealthVerity data, cited by CNBC, puts two-year prescription growth at 162%. HerKare reported that since 2021, overall HRT prescriptions are up 86%, with estrogen patches accounting for half of those scripts.

All major brands are affected. According to CleopatraRX, Climara, Vivelle-Dot, and generics from Teva and Mylan are all on indefinite backorder, with no resolution timeline from manufacturers. The American Society of Health-System Pharmacists lists three types of patches in shortage based on healthcare provider reports. The FDA, using a different methodology, had not declared an official shortage of estradiol as of the most recent reporting.

What Lit the Fuse

The proximate trigger was the FDA's November 2025 decision to begin removing long-standing black box warnings from HRT products. Those warnings had been in place since a 2002 study called the Women's Health Initiative suggested estrogen increased the risk of breast cancer, cardiovascular disease, and dementia.

Later analyses found the study's participants were older than the typical woman starting HRT and that the risks had been overstated. The FDA said its comprehensive review confirmed that conclusion.

"We removed the black box warnings on hormone replacement therapy to tell women the truth about the short-term and profound long-term public health benefits," FDA Commissioner Dr. Marty Makary said in an April 1 presentation to agency staff, as reported by Healthline. "Demand for hormone replacement therapy has surged since our announcement."

The demand surge, however, was already underway before the FDA acted. Doctors and CNBC both credit social media and figures like Oprah Winfrey with driving a broader cultural conversation about menopause that had been largely absent for years.

"The demand has actually come from more of the community of women," said Dr. Jessica Shepherd, chief medical officer of Hers. "This was much more brought about by social media."

What It Looks Like on the Ground

Dr. Francesca Turner, an Iowa physician, described the daily scramble to CNBC: "Between my nurse, patients' pharmacists and myself, we are doing this pretty much every day trying to figure out how to navigate this for our patients."

Dr. Susan Loeb-Zeitlin, director of the Women's Midlife Center at Weill Cornell Medicine, told CNBC: "You can get them, but it takes a lot of time and effort when we're all so busy at this time of our lives."

Doctors prefer transdermal delivery — patches, creams, gels — because the hormone absorbs through the skin rather than passing through the liver, which is considered safer than oral administration, Loeb-Zeitlin explained.

The shortage compounds an existing problem. More than 1 million U.S. women begin menopause each year, according to the National Institutes of Health, cited by Healthline. A multi-year supply gap in a first-line treatment for that population is a real public health issue, not a niche inconvenience.

The Strongest Counterpoint

Critics of the FDA's timing argue the agency should have anticipated the demand surge before removing the black box warning, or at minimum coordinated with manufacturers to ensure supply could meet the incoming wave. Removing a warning that had suppressed demand for 20 years, without a parallel effort to expand manufacturing capacity, was a sequencing failure regardless of whether the science behind the label change was correct. The FDA has not publicly addressed why supply readiness was not part of the rollout plan.

The supply-side pressure is also partly a tariff and trade problem, according to HerKare. Many of the raw ingredients used in estrogen patches come from overseas, and trade disruptions and tariffs have added friction to an already strained supply chain.

What Women Can Actually Do

Neither CNBC nor Healthline tells women to simply wait it out, and that is the right instinct. Several FDA-approved alternatives exist.

Healthline and HerKare both list oral estradiol tablets, transdermal gels and creams, sprays, hormone pellets, and vaginal suppositories as viable substitutes. CleopatraRX notes that compounded oral estriol, used safely in Europe for more than 40 years, may be worth discussing with a prescriber, particularly for women whose primary concern is cognitive symptoms like brain fog and memory issues, given that estriol targets receptors more concentrated in the brain.

The consistent message from physicians: do NOT stop HRT abruptly without a provider's guidance. Stopping cold can cause symptoms to return fast and hard.

How Long Will This Last

Reuters reported the shortage could last up to three years. CleopatraRX's analysis puts the expected duration through the end of 2026 at minimum. CNBC cited a projection of at least one year for manufacturers to catch up. None of those timelines agree with each other. Nobody actually knows.

Dr. G. Thomas Ruiz, an OB-GYN at MemorialCare Orange Coast Medical Center in Fountain Valley, California, told Healthline the shift in his own practice has been dramatic. "As soon as the FDA changed its black box warning, I got so many patients who are no longer fearful."

That fear had kept a generation of women away from a treatment most of them could safely use. Removing it was the right call on the science. Whether the rollout was managed well enough for patients who needed supplies on day one is the question that still does not have a clean answer.